中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (12): 2693-2694.doi: 10.4103/1673-5374.373710

• 观点:退行性病与再生 • 上一篇    下一篇

细胞替代治疗帕金森病:进展和挑战

  

  • 出版日期:2023-12-15 发布日期:2023-06-15

Cell replacement for Parkinson’s disease: advances and challenges

Bin Xiao, Eng-King Tan*   

  1. Department of Neurology, National Neuroscience Institute, Singapore (Xiao B, Tan EK)
    Neuroscience and Behavioral Disorders Program, Duke-NUS Medical School, Singapore (Tan EK)
  • Online:2023-12-15 Published:2023-06-15
  • Contact: Eng-King Tan, MD, FRCP, gnrtek@sgh.com.sg.
  • Supported by:
    The authors thank the Singapore Ministry of Health’s National Medical Research Council (Open Fund Large Collaborative Grant (MOH-000207) and Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/0030/2018) to EKT, CS-IRG-NIG, OF-YIRG and TA award to BX) for their support. The authors apologize for not being able to cite most of the relevant work, owing to reference limitations. 

摘要: https://orcid.org/0000-0003-2977-9743 (Eng-King Tan)

Abstract: Parkinson’s disease (PD), characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) of the midbrain, is a prototype neurological disease that is suitable for cellular replacement therapy. Levodopa has been utilized to replace the insufficient dopamine released by degenerating DA neurons since the 1960s and it remains the cornerstone of PD treatment. However, as the disease progresses, the diminishing DA neurons become inadequate to convert administered levodopa to functional dopamine, and the affected axonal projections fail to deliver dopamine to target brain regions. As a result, the dopamine replacement eventually loses its efficacy after the initial honeymoon period, and chronic levodopa therapy is associated with debilitating side effects, including motor and non-motor complications.